Levothyroxine: Conventional and Novel Drug Delivery Formulations
Endocrine Reviews · 08.05.2023 · 44 (3) · 393-416
DOI: 10.1210/endrev/bnac030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 22.11.2022. Verfasst von Hanqing Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, People's Republic of China. Hauptthemen laut MEDLINE: Thyroxine, Hypothyroidism. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 279 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Fundamental Research Funds, Central Universities.
Abstract (Originalsprache)
Although levothyroxine is one of the most prescribed medications in the world, its bioavailability has been reported to be impaired by many factors, including interfering drugs or foods and concomitant diseases, and persistent hypothyroidism with a high dose of levothyroxine is thus elicited. Persistent hypothyroidism can also be induced by noninterchangeability between formulations and poor compliance. To address these issues some strategies have been developed. Novel formulations (liquid solutions and soft gel capsules) have been designed to eliminate malabsorption. Some other delivery routes (injections, suppositories, sprays, and sublingual and transdermal administrations) are aimed at circumventing different difficulties in dosing, such as thyroid emergencies and dysphagia. Moreover, nanomaterials have been used to develop delivery systems for the sustained release of levothyroxine to improve patient compliance and reduce costs. Some delivery systems encapsulating nanoparticles show promising release profiles. In this review, we first summarize the medical conditions that interfere with the bioavailability of oral levothyroxine and discuss the underlying mechanisms and treatments. The efficacy of liquid solutions and soft gel capsules are systematically evaluated. We further summarize the novel delivery routes for levothyroxine and their possible applications. Nanomaterials in the levothyroxine field are then discussed and compared based on their load and release profile. We hope the article provides novel insights into the drug delivery of levothyroxine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, People's Republic of China.
- Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Ministry of Education), School of Pharmaceutical Sciences, Wuhan University, Wuhan 430060, Hubei, People's Republic of China.
ORCID-Profile: Hanqing Liu, Wei Li, Wen Zhang, Shengrong Sun, Chuang Chen
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Fundamental Research Funds
- Central Universities
- Science and Technology Major Project of Hubei Province
- Next-Generation AI Technologies
Zitieren
APA
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023). Levothyroxine: Conventional and Novel Drug Delivery Formulations. Endocrine Reviews, 44(3), 393-416. https://doi.org/10.1210/endrev/bnac030
Vancouver
Liu H, Li W, Zhang W, Sun S, Chen C. Levothyroxine: Conventional and Novel Drug Delivery Formulations. Endocrine Reviews. 2023;44(3):393-416. doi:10.1210/endrev/bnac030
BibTeX
@article{Liu2023,
author = {Liu, Hanqing and Li, Wei and Zhang, Wen and Sun, Shengrong and Chen, Chuang},
title = {Levothyroxine: Conventional and Novel Drug Delivery Formulations},
journal = {Endocrine Reviews},
year = {2023},
volume = {44},
number = {3},
pages = {393--416},
doi = {10.1210/endrev/bnac030}
}
EUVIMED